Skip to content

News

Ovarian Cancer Research Alliance Launches Community Accelerated Research Exchange, a Global AI-Powered Ecosystem to Transform Gynecologic Cancer Research

Ovarian Cancer Research Alliance Launches Community Accelerated Research Exchange, a Global AI-Powered Ecosystem to Transform Gynecologic Cancer Research

Platform, powered by AWS, connects patients, researchers, and clinicians to accelerate breakthroughs in gynecologic cancers [NEW YORK, NY – May 8, 2026] — Ovarian Cancer Research Alliance (OCRA) today announced the launch of the Community Accelerated Research Exchange, a first-of-its-kind, global, AI-powered ecosystem designed to transform how gynecologic cancer research is conducted—accelerating breakthroughs by connecting … Continued

The Overview: April 2026

The Overview: April 2026

Accelerating the Mission: OCRA President & CEO Audra Moran Named a Crain’s 2026 Notable Leader in Health Care Ovarian Cancer Research Alliance (OCRA) is proud to share that President and CEO Audra Moran has been named a Crain’s New York Business 2026 Notable Leader in Health Care—an annual recognition honoring executives whose leadership, innovation, and … Continued

OCRA President & CEO Audra Moran Named Crain’s 2026 Notable Leader in Health Care

OCRA President & CEO Audra Moran Named Crain’s 2026 Notable Leader in Health Care

Audra Moran, President and CEO of Ovarian Cancer Research Alliance (OCRA), has been recognized as a Crain’s New York Business 2026 Notable Leader in Health Care. Crain’s annual recognition spotlights health care executives whose leadership, innovation, and community commitment set a high bar for the field. Honorees are selected based on demonstrated impact, both within … Continued

OCRA Sponsors NCCN Guidelines for Cervical, Ovarian, and Uterine Cancer Patients

OCRA Sponsors NCCN Guidelines for Cervical, Ovarian, and Uterine Cancer Patients

This article was updated in April 2026 to reflect NCCN’s release of the 2026 Guidelines for Uterine Cancer Patients. OCRA is a proud sponsor of the 2026 Patient Guidelines for Cervical Cancer and Uterine Cancer, and the 2025 Patient Guidelines for Ovarian. We believe ensuring access to clear, understandable information is critical. NCCN provides wonderful … Continued

FDA Approves Lifyorli Plus Abraxane for Platinum-Resistant Ovarian Cancer

FDA Approves Lifyorli Plus Abraxane for Platinum-Resistant Ovarian Cancer

On March 25, 2026, the U.S. Food and Drug Administration (FDA) approved Lifyorli (relacorilant), made by Corcept Therapeutics, in combination with Abraxane (nab-paclitaxel) for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior lines of treatment, including prior Avastin (bevacizumab).  The approval follows last month’s FDA … Continued

The Overview: March 2026

The Overview: March 2026

OCRA’s Annual Advocacy Day Draws Survivors and Caregivers from Across the Country More than 120 gynecologic cancer survivors, caregivers, researchers and supporters from nearly forty states filled the halls of the U.S. Capitol on Tuesday, March 17—dressed in teal, the color of ovarian cancer awareness—as Ovarian Cancer Research Alliance (OCRA) held its annual Spring Advocacy Day. The … Continued

April Programs: New Offerings, Fresh Topics, and More

April Programs: New Offerings, Fresh Topics, and More

April is a full month at OCRA, with several new programs joining our ongoing lineup of workshops, educational sessions, and community events. Whether you’re looking for practical guidance, clinical information, or simply a chance to connect and create, there’s something here for you. New and Expanded Programs Advanced Care Planning Workshop Series April 6, 13, … Continued

OCRA’s Advocate’s Corner: March 2026

OCRA’s Advocate’s Corner: March 2026

Written by Julia Thayer, Associate Director, Advocacy This month, more than 120 OCRA Advocate Leaders traveled to Washington, DC for Advocacy Day—braving snowstorms, severe weather, and even a partial government shutdown to make their voices heard on Capitol Hill. We kicked things off with a full day of training, where the group built skills, shared stories, and … Continued

OCRA’s Spring Advocacy Day Brings Impact to Capitol Hill

OCRA’s Spring Advocacy Day Brings Impact to Capitol Hill

On March 17, 122 Advocate Leaders from nearly 40 states and Washington, DC, converged on Capitol Hill for OCRA’s Spring Advocacy Day. Together, they held 158 meetings with Congressional offices, carrying a clear message: Congress must sustain and build on its commitment to ovarian and gynecologic cancer research. The energy and reach of this year’s … Continued

Cool Hand Frank Names OCRA Featured Cause for March

Cool Hand Frank Names OCRA Featured Cause for March

Cool Hand Frank, a digital publication that spotlights nonprofits making a difference, has named Ovarian Cancer Research Alliance (OCRA) its featured cause for March 2026, spotlighting OCRA’s work in advancing ovarian and gynecologic cancer research and supporting patients and their loved ones. The publication cited a deeply personal connection to the cause, with the author … Continued

New AI Accelerator Grant Captures Health and Science Media Attention

New AI Accelerator Grant Captures Health and Science Media Attention

OCRA is excited to see the work fueled by our new AI Accelerator Grant resonating with a broad array of audiences. Since the Global Ovarian Cancer Research Consortium announced the inaugural AI Accelerator Grant on February 19, coverage has appeared across health, science, and business media outlets. The $1 million global research award—with an additional … Continued

Stay Informed

Get email updates about research news, action alerts, and ways to join the fight.

Our website uses cookies to ensure you get the best experience. By continuing to use this website, you indicate that you have read and agree to our Terms of Use and Privacy Policy.